There are some skin conditions we're very familiar with: spots during adolescence, allergic rashes, sunburn. But others are ...

Patients with rosacea and skin of color are more likely to have severe disease phenotypes when compared with White patients with rosacea.

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...

If you have rosacea, you must be experiencing redness and small, red bumps on your face for a long time. These symptoms may last for a few weeks or months and then disappear for a while. The problem ...

About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 (revakinagene taroretcel) from Neurotech Pharmaceuticals Inc., a privately held ...

The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024. Interested parties are invited to visit Journey Medical’s booth 2181 to learn about ...

telangiectasia, inflammatory lesions, and ocular manifestations. Among the more recently approved treatments for rosacea — and among products and drug indications under study — “notice there ...

While in high school, I finally took the initiative to find answers for my condition, and that's when my dermatologist told me about rosacea. Rosacea is a chronic skin condition characterized by ...

Rosacea is more common among fair-skinned people ages 30 to 50 years. It's slightly more common in females rather than males. Even so, rosacea can develop at any age, even during childhood. These ...